First patient undergoes new personalized cancer immunotherapy at UCSD Health, despite COVID-19 pandemic

Cancer patient Bernard Thurman became the first to undergo a type of investigational cell therapy at UC San Diego Health.
On Dec. 8, Bernard Thurman became the first patient to undergo an investigational cell therapy at UC San Diego Health that uses a patient’s own, lab-grown tumor infiltrating lymphocytes (immune cells) in an effort to destroy cancer.
(UC San Diego Health)

Since 2016, Bernard Thurman has undergone traditional treatments, experimental therapies and surgeries to counter the cancer within him, but nothing has eradicated the disease. Earlier this year, the oncologists in Los Angeles who were treating him referred Thurman to a personalized cancer therapy trial being developed at Moores Cancer Center at UC San Diego Health.

“Truly, I am running out of options as far as treatment goes,” said Thurman, whose cancer developed in his tonsils and has since spread to his lungs.

On Dec. 8, Thurman became the first patient to undergo an investigational cell therapy that uses a patient’s own, lab-grown immune cells, specifically tumor infiltrating lymphocytes, or TIL, in an effort to destroy his cancer.

“The latest immunotherapies, both the FDA-approved and the experimental, were proving ineffective. Obviously, it was time to go in a different direction,” Thurman said.

Thurman met with Dr. Ezra Cohen, associate director for translational science at Moores Cancer Center, in mid-March to discuss the investigational cell therapy.

Shortly after the meeting, COVID-19 swept the country, forcing hospitals to rethink which procedures could continue and which would need to be paused. Because the TIL trial requires that patients be hospitalized, it was put on hold.

“At that time, we did not know what to anticipate in terms of the number of patients that would be admitted because of COVID-19,” Cohen said. “We made a conscious decision that any clinical trial that required an inpatient stay would be temporarily suspended.”

Thurman was disappointed.

“Don’t let the pandemic make you decide to put off cancer treatment,” Thurman said. “You may or may not get COVID, but cancer will kill you if you don’t treat it. So don’t delay it.”

Knowing the urgency of treatment, Cohen, a head and neck oncologist, suggested an alternative trial.

“We treated Mr. Thurman on an initial clinical trial with a different type of immunotherapy, an antibody, and he did fairly well at the beginning,” Cohen said. “But again his cancer began to grow and, unfortunately, progressed.”

While the COVID-19 pandemic continues to sicken people worldwide, UC San Diego Health has resumed previously paused medical services. That allowed Cohen and colleagues Dr. Gregory Daniels and Dr. Aaron Miller to reinitiate the Phase I TIL trial.

After seeing that Thurman’s cancer was unabated on the immunotherapy trial, he was enrolled as the first patient and received personalized TIL therapy.

“Treating our first patient with his own cells generated at UC San Diego marks a milestone following years of
preparation leveraging the core strengths of the cancer center — patient care, research and collaboration,” said Daniels, an oncologist specializing in skin and head and neck cancers and protocol principal investigator for the TIL trial.

TIL therapy has been around for decades, with some success in treating melanoma — the most serious form of skin cancer.

Together, UC San Diego and La Jolla Institute for Immunology researchers are taking TIL therapy a step further by selecting the T-cells that are most likely to be responsive against an individual’s cancer. They also are expanding the therapy to treat melanoma and head and neck cancers.

“Cell therapy has been proven effective for a number of different patients, but we want to improve upon it,” said Miller, a medical oncologist. “We want to make it more effective, less toxic and more applicable to a broader population of cancer patients.”

Bernard Thurman was referred to Moores Cancer Center at UC San Diego Health in a last-ditch effort to halt his cancer.
Bernard Thurman has undergone a variety of cancer therapies; none has eradicated the disease. He was referred to Moores Cancer Center at UC San Diego Health in a last-ditch effort to halt his cancer.
(UC San Diego Health)

Engineering Thurman’s TIL therapy involved a weeks-long, personalized process that began with Thurman undergoing a tumor biopsy at Jacobs Medical Center at UCSD Health in October.

Tissue samples were then sent to the La Jolla Institute for Immunology, where a team led by Stephen Schoenberger and Bjoern Peters developed a novel technology platform to identify mutations recognized by the patient’s immune system.

Early funding from the Immunotherapy Foundation created the infrastructure to develop the process, which was first used to develop a personalized cancer vaccine trial in 2018.

An algorithm is used to isolate tumor-infiltrating lymphocytes, a type of T-cell, with the strongest response against Thurman’s cancer mutations.

“We are taking the patient’s tumor, sequencing the protein coding portion of the genome, finding out which mutations can be recognized by the patient’s immune system, and then looking for the TIL fragments that contain those T-cells,” said Schoenberger, an adjunct professor at the UC San Diego School of Medicine. “If we can identify which TIL can recognize the mutations that are selectively expressed in the tumor, selectively grow those and reinfuse them to the patient, we will
hopefully have a more potent and more effective therapy. That’s our advance.”

Once the T-cells that appeared to be initiating the strongest immune system response to Thurman’s cancer are identified, a
team led by Dr. Dan Kaufman at the Advanced Cell Therapy Laboratory at UCSD multiplies the specified T-cells by the

The cells are the patient’s own, simply lab-grown.

At Jacobs Medical Center, Thurman underwent an infusion of the engineered cells and a high-dose interleukin-2, a biologic therapy used to boost T-cell response in cancer therapy.

Ideally, within weeks, the TIL therapy will shrink tumors.

“All of us involved in this research project want one thing and one thing only, and that is for patients to get better and to offer new effective therapies to patients with cancer,” Schoenberger said.

Thurman wants that, too. He said he is optimistic, but also understands that he is the first patient to receive the experimental, personalized cancer therapy. He thinks others should enroll in clinical trials, too.

“Clinical trials are a lifeline,” he said. “Give it a shot. You may literally have nothing to lose. It may be beneficial personally. It may not. But it will further research for other patients down the road and hopefully help others in the future.”

For more information about the TIL trial, visit ◆